Our CSO Agapitos joined RoukenBio in 2018. He originally trained as a pharmacist, followed by an MSc in Immuno-Pharmacology & MPhil in Pharmacology (Uni of Strathclyde) and a PhD in Immunology/Rheumatology (Uni of Glasgow). As a post-doctoral researcher in the Institute of Infection, Immunity & Inflammation he specialised in the role of T cells in inflammatory arthritis and published several papers on the subject.
In 2015, he moved to industry focusing on the development of T cell therapies against cancer. There he led process and product development activities, established CAR-T programs and had a critical role in securing several millions of non-dilutive funding.
Agapitos then joined RoukenBio, where he established the translational immunology business unit, leading the development of several bespoke immunology assays such as our T cell exhaustion, T-cell mediated cytotoxicity assays etc., significantly expanding the company’s service portfolio.
In 2020, Agi became CSO and now strategically leads all R&D and new service development. He is co-inventor in several patents in the field of T cell therapies and cell line development.
Resources
Research Posters
10 November 2026
|5 min read
This research poster presents an integrated, human-relevant assay cascade for antibody-drug conjugate (ADC) evaluation, connecting target engagement and intracellular payload delivery with target-density dependence, tumour-cell killing, Fc-mediated immune activity and response within the tumour microenvironment. By combining controlled cellular models, primary human immune assays and patient-derived tumour models, the approach generates mechanism-linked insights to support more informed ADC candidate ranking and lead selection
Research Posters
4 November 2026
|5 min read
This research poster presents a modular, patient-derived 3D colorectal cancer model incorporating tumoroids, tumour-infiltrating lymphocytes (TILs) and cancer-associated fibroblasts (CAFs). By recreating key immune and stromal interactions within the tumour microenvironment and enabling assessment of therapeutic responses, the platform provides a translational approach for evaluating novel immuno-oncology therapeutics.
Research Posters
28 October 2026
|5 min read
This research poster presents a human antigen-specific in vitro CD8+ T-cell exhaustion model designed to replicate chronic tumour antigen stimulation. By assessing inhibitory receptor expression, cytokine production and cytolytic activity, the model supports investigation of T-cell exhaustion and evaluation of candidate immunomodulators.
